Section - CAP Smart Prend

05. Efficacité à long terme de l’escitalopram chez les adolescents atteints de trouble dépressif majeur

Publié sur 1 avril 2024 Certification date d'expiration: 1 avril 2027

David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.

Professor of Psychiatry - University of Maryland School of Medicine

Points Clés

This study did not demonstrate that escitalopram is superior to placebo in preventing relapse after 48 weeks of treatment compared with 12 weeks.
Results are not definitive due to limitations, such as high placebo response rates and lower-than-expected relapse rates in adolescents with MDD.

Pour débloquer cet audio vous avez besoin de devenir un Silver, Gold, Silver extended, Gold extended, Gold – fr, Silver – fr, Silver extended – fr ou Gold extended – fr Membre.

Consultez Notre Programme d'ÉMC

Téléchargements pour un Accès Hors ligne

Télécharger Fichier Audio (MP3)

Version texte

Bonjour, ici David Rosenberg. Dans ce « Smart Take » consacré à la CAP — la psychiatrie de l’enfant et de l’adolescent — nous examinerons un domaine crucial, bien que peu étudié, de cette discipline : l’efficacité à long terme des traitements antidépresseurs et leur capacité (ou leur incapacité) à prévenir les rechutes chez les adolescents ayant reçu un diagnostic de trouble dépressif majeur (TDM). Ce sujet est d’une importance capitale car, à ce jour, la pharmacothérapie destinée aux adolescents souffrant de trouble dépressif majeur demeure un domaine encore flou. Actuellement, seuls deux traitements sont approuvés par la FDA pour ce trouble chez les jeunes : la fluoxétine et l’escitalopram. Or, nous savons que de nombreux patients ne répondent pas du tout à ces traitements, ou n’y répondent que partiellement, ce qui entraîne la persistance de troubles fonctionnels.

Le risque de rechute demeure une question en suspens : combien de

Le déblocage de cette CAP Smart Take et gagner de 0.50 CMEs
Devenir un Silver, Gold, Silver extended, Gold extended, Gold – fr, Silver – fr, Silver extended – fr ou Gold extended – fr Membre.

Obtenez L'Accès Instantané

Avez déjà un compte? Signe dans

Learning Objectives:

Recognize that at 3-year follow-up, 3 in 4 pediatric patients with OCD were in clinical remission.
Recognize that although not statistically significant, combining probiotics with methylphenidate was associated with higher therapeutic efficacy in patients with ADHD.
Analyze the effectiveness of ECT in treating adolescents with severe depressive episodes and suicidality.
Recognize that studies to date support the safety of transcranial electrical stimulation and transcranial magnetic stimulation in children and adolescents.
Recognize that escitalopram was not superior to placebo for relapse prevention in adolescents with MDD.

Original Release Date: April 1, 2024

Expiration Date: April 1, 2027

Experts: David Rosenberg, M.D.

Medical Editor: Lorena Rodriguez, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@ml-staging.psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.